Individualized medication for intranasal dexmedetomidine in children: base on the pharmacokinetics and pharmacogenomics.

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1800015340

Enrollment

Unknown

Registered

2018-03-24

Start date

2018-03-28

Completion date

Unknown

Last updated

2018-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hemangioma

Interventions

Case series:dexmedetomidine

Eligibility

Sex/Gender

All

Age

No minimum to 6 Years

Inclusion criteria

Inclusion criteria: children with hemangioma of ASA physical status I-II, aged between 0 and 6 years, requiring general anesthesia will be enrolled in this study.

Exclusion criteria

Exclusion criteria: exclusion criteria included ASA physical status III or above, known allergy or hypersensitivity to dexmedetomidineand nose discharge.

Design outcomes

Primary

Measure	Time frame
success rate of sedation;blood concentration;gene detection;	—

Secondary

Measure	Time frame
blood pressure;heart rate;	—

Countries

China

Contacts

Public ContactBilian Li

Guangzhou Women and Children's Medical Centre

13570226780@126.com+86 13570226780

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026